In summary, under stress conditions, SETD7 may act as a tumour promoter reducing the response to therapy of LCa cells, since all studies [31,38,41,63,65] except one [62] found that downregulation of SETD7 or the inhibition of its activity increases sensitivity to chemotherapy. This evidence concerns the gene SETD7 and Leber congenital amaurosis.